The American healthcare sector in one line: the iShares S&P 500 Health Care Sector UCITS ETF (IUHC, ISIN IE00B43HR379) wraps the index’s pharma giants, insurers, device makers and biotech elders at a 0.15% TER, accumulating — the sector the textbooks call defensive and the era keeps repricing as anything but. The 661 impressions this site sees (German searchers asking for a “Bewertung” — an assessment) get exactly that: the paradox reviewed honestly.
Covered: what the sector basket actually holds, why “defensive growth” broke down this era, the policy risk that now prices everything, and the sector-fund placement rules. Verified against iShares and justETF, August 2026.
IUHC key facts
| Fact | Detail |
|---|---|
| ISIN | IE00B43HR379 (Acc) · EUR-hedged Dist IE00BMBKBZ46 |
| Ticker | IUHC |
| TER | 0.15% per year |
| Index | S&P 500 Health Care Sector (GICS) |
| Replication | Physical |
| Domicile | Ireland (UCITS) |
What the sector basket holds
GICS healthcare spans five distinct businesses sharing one customer: pharma majors (the patent-cliff-and-pipeline machines — the weight leaders), managed care (the US insurance giants — a purely American business model with purely American policy exposure), devices and equipment (the steadier surgical-and-diagnostics tier), biotech’s established elders (the profitable tier — the speculative frontier lives in dedicated innovation funds), and life-science tools (the picks-and-shovels of drug discovery). The composite’s traditional pitch — demographic demand, inelastic spending, innovation upside: defensive growth — and its modern complication: the era’s twin repricings, GLP-1 obesity drugs re-sorting winners within the sector while policy risk (drug-pricing negotiation, insurance reform politics) compressed multiples across it, delivering years of market-lagging returns precisely when the aging-demand thesis looked strongest. The paradox is the purchase: cheap defensiveness, priced for the policy weather.
This guide is part of our guide to choosing an all-world ETF.
Comparing UCITS funds? Take the decision workbook with you.
The ETF Comparison Workbook: TER, domicile, withholding and overlap checks in one printable spreadsheet.
The case, both ledgers
Bull: demographics compound regardless of politics (the aging West’s spending curve is the century’s most reliable demand forecast); the sector trades at a rare valuation discount to the index after its lagging era; GLP-1 economics mint one of the decade’s genuine growth stories inside a “defensive” wrapper; and innovation output (oncology, obesity, neuro) runs historically hot. Bear: US policy risk is structural and permanent — every pricing-reform cycle reprices the payers and pharma tiers; patent cliffs loom across the majors; and the sector’s defensive reputation keeps disappointing holders who bought it as a hiding place (it fell with markets in 2020 and 2022 and then missed the recoveries’ leadership). The synthesis: a legitimate valuation-plus-demographics satellite — the rare sector both cheap and structurally demanded — sized for policy amplitude the “defensive” label conceals.
Sector-fund placement: the standing rules
The IITU review’s framework transfers: sector funds are deliberate overweights atop market-weight cores — the world index already holds healthcare at its weight, and IUHC is the conviction dial. The sizing: 5–10% as a satellite, summed against any healthcare thematic holdings (the innovation funds overlap at the eldest tier). The US-only note: IUHC is American healthcare specifically — the European pharma champions live in Europe funds and global-sector alternatives; the US sector’s managed-care tier has no European equivalent, making IUHC the purest expression of the American system’s economics, politics included.
Taxes and buying
Irish accumulating UCITS standard (calculator); the EUR-hedged Dist class serves defined-horizon income takers. Euro lines liquid; plan availability broad.
Risks
- Policy cycles: US drug-pricing and insurance politics — the sector’s master variable, permanently live.
- Patent cliffs: the majors’ revenue resets on schedule; pipelines answer or don’t.
- Defensive disappointment: the label’s record this era — correlation up, cushion down.
- GLP-1 dispersion: the obesity-drug era re-sorts the sector’s winners violently in both directions.
Reader scenarios
“Is healthcare finally cheap enough to buy?” The discount is real and the demand thesis intact — the classic value-with-catalyst setup, paid for in policy amplitude. The automated-entry, 5–10% satellite framework prices it correctly; conviction lumps price it emotionally.
“IUHC or a global healthcare fund?” US-pure versus world — the global funds dilute the managed-care policy risk and the GLP-1 concentration alike; IUHC is the sharper instrument, the global tier the tamer. The thesis sentence decides.
“IUHC plus the healthcare-innovation fund — complementary?” A legitimate barbell — the sector’s profitable core plus its speculative frontier — summed as one healthcare budget; the HEAL review prices the frontier half.
“Does the defensive label mean anything anymore?” In earnings stability, still yes; in drawdown protection, the era says no — buy the demographics and the valuation, not the hiding place.
What to watch through 2026–2027
US policy calendar — pricing-negotiation rounds and election-cycle rhetoric; the multiple’s weather. GLP-1 economics — the growth story’s earnings delivery. Patent-cliff pipeline — the majors’ replacement math. The valuation gap — the entry thesis’s own metric.
The review’s last calibration: healthcare’s paradox — the surest demand, the noisiest politics — makes it the sector shelf’s best test of an investor’s actual philosophy. Value-and-patience investors see the discount and automate in; narrative investors see the policy headlines and stay out; both act consistently with their frameworks, and only the framework-free get hurt — buying the demographic story at the multiple’s top, selling the policy scare at its bottom. IUHC executes whichever decision you bring at an honest 0.15%; the review’s job was ensuring the decision arrives written.
Demographics compound; politics oscillate; the sized satellite holds through both.
“How large is the managed-care tier inside IUHC?” A structural double-digit slice — the insurance giants are top-ten weights, and their pure-US policy exposure is the fund’s sharpest differentiator from global healthcare alternatives; know the slice before buying the wrapper.
“Hedged class worth it for the sector?” Same standing framework — euro spenders on defined horizons only; the sector’s own volatility dwarfs the currency layer for everyone else.
“Global healthcare fund names to compare?” The Xtrackers and iShares world-healthcare wrappers carry the diluted version at similar fees — the purity fork this review framed; one healthcare budget, one instrument, chosen by the thesis sentence.
The century’s surest customer base, priced at a political discount — the paradox, held correctly, pays patience.
Buy the demand curve, rent the political weather, size for both — the sector, solved.
Patient capital meets patient demand — the rest is electoral noise, priced and survivable.
The waiting rooms fill regardless of who governs — own the arithmetic, rent the anxiety, collect the decade.
Quick-start checklist
- Write the thesis: valuation-plus-demographics, not a hiding place.
- Size 5–10% atop the market-weight core; sum with thematic healthcare.
- Automate entries through the policy noise.
- Class by need; hedged Dist for euro income takers.
- Annual review: policy cycle, cliffs, the discount’s evolution.
Verdict
IUHC wraps the era’s most interesting sector paradox at an honest 0.15%: the century’s surest demand curve trading at a discount, carrying policy risk that repriced the “defensive” label into fiction and a drug-era growth story the wrapper’s textbook image never advertised. As a sized, automated satellite for holders who buy the demographics and accept the politics, it’s the value seat of the sector shelf; as a hiding place from equity risk, it’s the era’s most documented disappointment. The Bewertung the searchers asked for: buy the paradox knowingly, or hold the market weight in peace.
The GLP-1 era: the sector’s internal revolution
The obesity-drug story deserves its own section because it rewired the sector IUHC holds. The revolution’s visible layer: the GLP-1 franchises minting pharma’s largest growth story in decades — obesity and diabetes markets expanding toward the largest addressable populations medicine has priced. The less-visible layers holders own: the losers’ repricing (device makers and care providers exposed to obesity-linked procedures sold off on projected demand erosion — some overdone, some prescient), the pipeline arms race (every major now runs metabolic programs; the dispersion between winners and also-rans widens yearly), and the payer politics (the drugs’ costs versus their long-term savings is the next policy battleground — the sector’s master risk wearing its newest costume). For the index holder the era’s meaning is structural: healthcare’s internal dispersion — the gap between its best and worst performers — runs at generational highs, which cuts both ways: the sector fund diversifies the single-name lottery (the index owns the winners at weight), and it dilutes the pure GLP-1 bet the era’s enthusiasts actually want (they hold the two famous names directly, with single-stock risk as the toll). IUHC’s honest GLP-1 pitch: the era’s economics at index weights, politics included — the diversified claim on medicine’s biggest story since statins.
One more scenario
“US election cycles and this fund — how much does the calendar matter?” Rhetoric moves the multiple every cycle; enacted policy moves it rarely — the sector’s history is repricing on proposals and recovering on gridlock. The automated-entry rule converts the calendar from threat to noise.
The demographic arithmetic: the thesis’s foundation, quantified
The sector’s demand case rests on arithmetic worth stating plainly. Healthcare spending per capita rises steeply with age — the over-65 cohort consumes multiples of the working-age average — and the developed world’s over-65 share is on a decades-long climb the birth records already wrote: the spending curve is demographic destiny, immune to elections and cycles alike. Layer the innovation economics: each therapeutic breakthrough (the GLP-1 era’s exhibit) expands treatable populations and spending simultaneously — medicine’s progress is, financially, a demand generator. Against that foundation, the sector’s era of lagging returns reads correctly: not a demand problem (spending grew throughout) but a pricing-of-the-equity problem — the policy-risk discount widening as the multiple compressed — which is precisely the setup value investors historically want: durable demand at a discounted rating, paid for in political amplitude. The forward decade’s referendum: whether the discount unwinds (the demographic earnings grinding the multiple back), stays (policy risk as permanent toll), or widens (reform actually landing). The demographic engine runs regardless; the equity’s rating is the only open question — and the sized-satellite framework exists exactly for questions of that shape.
Frequently asked questions
What are IUHC’s biggest holdings?
The US pharma and insurance giants lead — the live top-ten on the fund page; GLP-1 era weights have re-sorted the leaders visibly.
Why did healthcare lag the market for years?
Policy-risk multiple compression plus the market’s mega-tech leadership — the sector’s earnings grew while its rating shrank; the discount is that history’s residue.
Does IUHC hold Novo Nordisk or European pharma?
No — the S&P 500 universe is US-listed; the European champions live in regional and global funds. The GLP-1 exposure arrives via the American players.
Is there a global healthcare sector UCITS ETF?
Several — world-healthcare funds blend the US core with Europe and Japan at similar fees; the choice is purity versus dilution of the US policy variable.
How volatile is the sector versus the S&P?
Historically calmer in earnings, comparable in price this era — the defensive statistics eroded as policy beta rose; expect market-like swings with different timing.
What is the hedged Dist class for?
Euro income takers wanting sector payouts without dollar noise — the usual hedge toll applies; the Acc flagship serves everyone else.
What share of the S&P 500 is healthcare?
Historically among the largest sector weights — the live figure floats with the era’s repricings; the sector fund is that slice at 100%.
How does IUHC compare to the world healthcare ETFs?
US-pure versus global — the world funds add the European champions and dilute US policy risk; IUHC is the sharper, more American instrument.
Cited sources: iShares fund data, justETF data, and S&P sector index data. Verify current fund figures before investing. Educational content, not financial advice.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →